目的 探討復方羚角降壓片聯(lián)合福辛普利鈉片治療原發(fā)性高血壓的臨床療效。方法 選取2019年1月—2019年12月在河南省中醫(yī)藥研究院附屬醫(yī)院就診的138例原發(fā)性高血壓患者，隨機分為對照組和治療組，每組各69例。對照組口服福辛普利鈉片，10 mg/次，1次/d；治療組在對照組的基礎上口服復方羚角降壓片，3片/次，3次/d。兩組患者均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者血壓變異性，血清血管內(nèi)皮生長因子（VEGF）、內(nèi)皮素1（ET-1）和一氧化氮（NO）、超敏C反應蛋白（hs-CRP）和白細胞介素6（IL-6）水平。結(jié)果 治療后，治療組總有效率為94.20%，顯著高于對照組的82.61%（P<0.05）。治療后，兩組24 h收縮壓（SBP）、24 h舒張壓（DBP）、收縮壓變異性（SBPV）和舒張壓變異性（DBPV）均顯著降低（P<0.05），與對照組相比，治療組降低更顯著（P<0.05）。治療后，兩組VEGF、ET-1、hs-CRP和IL-6水平均顯著下降，而NO水平顯著升高（P<0.05），且治療組這些指標水平顯著優(yōu)于對照組（P<0.05）。結(jié)論 復方羚角降壓片聯(lián)合福辛普利鈉片治療原發(fā)性高血壓療效顯著，能有效改善患者血管內(nèi)皮細胞功能和炎癥狀態(tài)，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of Compound Lingjiao Jiangya Tablets combined with Fosinopril Sodium Tablets in treatment of primary hypertension. Methods Patients (138 cases) with primary hypertension in the Affiliated Hospital of Henan Academy of Chinese Medicine from January 2019 to December 2019 were randomly divided into control and treatment groups, and each had 69 cases. Patients in the control group were po administered with Fosinopril Sodium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Lingjiao Jiangya Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure variability, and the serum levels of VEGF, ET-1, NO, hs-CRP and IL-6 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 94.20%, which was significantly higher than 82.61% in the control group (P<0.05). After treatment, the 24 h SBP, 24 h DBP, SBPV, and DBPV levels in two groups were significantly decreased (P<0.05), and compared with the control group, the treatment group decreased more significantly (P<0.05). After treatment, the serum levels of VEGF, ET-1, hs-CRP and IL-6 in the two groups were significantly decreased, while the levels of NO were significantly increased (P<0.05), and the levels of these indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Compound Lingjiao Jiangya Tablets combined with Fosinopril Sodium Tablets has a significant clinical efficacy in treatment of primary hypertension, can significantly improve the vascular endothelial cell function and decrease inflammatory status, which has a certain clinical application value.

R972